Tecentriq
Exelixis’ Kinase Blocker Zanzalintinib Sets New Survival Standard in Third-Line Metastatic Colorectal Cancer, Paving Way for FDA Review
Exelixis; zanzalintinib; kinase inhibitor; colorectal cancer; STELLAR-303 trial; Tecentriq; regorafenib; overall survival; third-line therapy; FDA submission
Tecentriq Demonstrates Survival Benefit in ctDNA-Guided Bladder Cancer Treatment at ESMO 2025
Tecentriq; atezolizumab; ctDNA-guided therapy; IMvigor011; bladder cancer; muscle-invasive bladder cancer; adjuvant treatment; overall survival; disease-free survival; ESMO 2025; Signatera; Genentech; Roche
Exelixis’ Phase 3 Colorectal Cancer Data Sends Stock Higher
Exelixis; zanzalintinib; colorectal cancer; Phase 3 trial; STELLAR-303; Tecentriq; Regorafenib; clinical trial results; stock surge
Jazz Releases Full Survival Data for Zepzelca in Lung Cancer at ASCO 2025
Jazz Pharmaceuticals; Zepzelca; lurbinectedin; lung cancer; small cell lung cancer; Tecentriq; atezolizumab; IMforte trial; overall survival; progression-free survival; ASCO 2025
Tempest Seeks Strategic Partners to Launch Phase 3 Liver Cancer Trial Amid Funding Challenges
Tempest Therapeutics , Amezalpat , Phase 3 Trial , Liver Cancer (HCC) , Strategic Partnerships , Biotech Funding , PPAR⍺ Antagonist , Clinical Oncology , FDA Clearance , Tecentriq and Avastin Combination Therapy
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
Roche Secures FDA Approval for Subcutaneous Ocrevus and Tecentriq, Lilly Gains Approval for Eczema Treatment
FDA approvals, Roche, Subcutaneous products, Ocrevus, Tecentriq, Lilly, Eczema treatment, Pharmaceutical industry, Biopharma news
FDA Approves Roche’s Tecentriq Hybreza: First Subcutaneous PD-L1 Cancer Immunotherapy
Tecentriq Hybreza, Subcutaneous PD-L1 inhibitor, Cancer immunotherapy, FDA approval, Roche, Atezolizumab, Hyaluronidase-tqjs, Enhanze drug delivery technology
Roche Secures FDA Approval for Subcutaneous Tecentriq Hybreza, Enhancing Cancer Treatment Options
Roche, FDA Approval, Tecentriq Hybreza, Subcutaneous Administration, Cancer Immunotherapy, PD-L1 Inhibitor, Halozyme Therapeutics, Enhanze Drug Delivery Technology
Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq